Locanabio, Inc.

Locanabio, Inc., founded in 2016, is at the forefront of developing RNA-targeting gene therapies to address significant unmet medical needs. Their innovative approach focuses on correcting disease-causing RNA, utilizing a proprietary platform that includes advanced systems like snRNA, Cas13d, and PUF. This technology offers potential for long-lasting therapies with just one administration, without altering cell DNA.

Headquartered in the United States, Locanabio harnesses expertise in Biotechnology and Health Care to tackle rare genetic neuromuscular and neurodegenerative diseases. The company's capabilities are underscored by a dedicated leadership team and distinguished scientific advisors. Locanabio’s potential caught the attention of investors, culminating in a $100.00M Series B investment in December 2020 from prominent players such as Arch Venture Partners, GV, Lightstone Ventures, and others. Locanabio stands well-positioned to revolutionize the space with next-generation genetic medicines.